Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7441.084 | 0.9902 | 0.9767 | 0.8431 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7441.084 | 0.9824 | 0.9584 | 0.8431 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7441.084 | 1.0126 | 1.0300 | 0.8431 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7441.084 | 0.9374 | 0.8523 | 0.8431 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7441.084 | 0.7959 | 0.5255 | 0.8431 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7441.084 | 0.0799 | -0.9002 | 0.8431 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7441.084 | 0.0310 | -0.9676 | 0.8431 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7442.085 | 0.9668 | 0.9196 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7442.085 | 0.9935 | 0.9843 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7442.085 | 0.9944 | 0.9864 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7442.085 | 1.0034 | 1.0082 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7442.085 | 0.9853 | 0.9645 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7442.085 | 0.9443 | 0.8654 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7442.085 | 0.9509 | 0.8815 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7442.085 | 0.8930 | 0.7433 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7442.085 | 0.1751 | -0.7588 | 0.8237 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7443.084 | 0.9544 | 0.9078 | 0.9878 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7443.084 | 0.9527 | 0.9042 | 0.9878 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7443.084 | 0.9723 | 0.9440 | 0.9878 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7443.084 | 0.9247 | 0.8476 | 0.9878 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7443.084 | 1.0427 | 1.0865 | 0.9878 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7443.084 | 1.0506 | 1.1026 | 0.9878 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7443.084 | 0.4314 | -0.1461 | 0.9878 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7443.084 | 0.3022 | -0.4045 | 0.9878 | |
| HCC1428 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7443.084 | 0.1331 | -0.7404 | 0.9878 |